Conclusions: ATG1144 specifically binds to human CD24 with high sensitivity as demonstrated by IHC staining. The development ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

AstraZeneca to buy in vivo cell therapy company, EsoBiotec for US$ 1billion: Cambridge, UK Tuesday, March 18, 2025, 10:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceu ...

expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in vivo CAR T with ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company EsoBiotec to advance its cell therapy ambitions.

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape detection. This innovation, called ALA-CART, helps the immune system better ...